The management and outcome of chronic graft-versus-host disease

Area of Science:

• Hematology
• Immunology
• Transplantation Medicine

Background:

• Chronic graft-versus-host disease (cGVHD) is a frequent complication after allogeneic haematopoietic cell transplantation (HCT).
• It is the primary cause of non-relapse mortality and significantly affects transplant survivors' quality of life.
• Despite advances in HCT, cGVHD incidence, morbidity, and mortality have shown minimal improvement.

Purpose of the Study:

• To highlight the persistent challenges in managing cGVHD.
• To emphasize the need for improved understanding of cGVHD pathogenesis.
• To underscore the necessity for validated grading systems and outcome measures to advance clinical research.

Main Methods:

• Review of existing literature on cGVHD prophylaxis and treatment strategies.
• Analysis of factors contributing to the lack of progress in cGVHD management.
• Discussion of current treatment standards and the need for comparative efficacy studies.

Main Results:

• Prophylaxis strategies have been largely unsuccessful and may impair the graft-versus-leukaemia (GVL) effect.
• Corticosteroids and calcineurin inhibitors remain the standard primary treatment.
• There is a lack of standard therapy for corticosteroid-refractory cGVHD, necessitating further research.

Conclusions:

• Infection is the leading cause of mortality in cGVHD patients, mandating antimicrobial prophylaxis.
• A multidisciplinary approach is crucial for addressing the physical and psychological impacts of cGVHD.
• Systematic research comparing different therapeutic approaches is urgently required to improve patient outcomes.